Le 31 décembre 2019, l’Organisation mondiale de la Santé (OMS) a été informée qu’un groupe de cas de pneumonie dont la cause était inconnue avait été détecté à Wuhan, dans la province de Hubei, en Chine
Le 7 janvier 2020, les autorités chinoises ont identifié un virus, le SARS-CoV-2, comme agent étiologique de cette maladie à laquelle l’OMS a donné le nom de maladie à coronavirus 2019 (COVID-19) le 11 février 2020. Dans le cadre de la riposte de l’OMS à cette flambée épidémique, un schéma directeur en matière de recherche-développement a été établi pour accélérer la mise au point de diagnostics, de vaccins et de traitements pour ce nouveau coronavirus.
Sous la coordination de l’OMS, un groupe d’experts venant d’horizons divers s’attèle à mettre au point des vaccins contre la COVID-19.
Ce groupe lance un appel pour que chacun respecte les recommandations visant à prévenir la transmission du virus responsable de la COVID-19 et à protéger la santé des personnes. Il remercie également toutes celles et tous ceux qui accordent leur confiance au monde scientifique.
Déclaration
Scientifiques, médecins, bailleurs de fonds et fabricants, nous nous sommes unis dans le cadre d’une collaboration internationale coordonnée par l’Organisation mondiale de la Santé (OMS) dans le but d’accélérer la mise à disposition d’un vaccin contre la COVID-19. Bien qu’il faille du temps pour mettre au point un vaccin destiné à un usage général, celui-ci pourrait, à terme, être essentiel pour maîtriser cette pandémie planétaire.
En attendant, nous saluons l’application de mesures d’intervention auprès des populations qui permettent de ralentir la propagation du virus et de protéger les personnes, y compris les populations vulnérables, et nous nous engageons à tirer parti du temps que fait gagner l’adoption de telles mesures généralisées pour mettre au point un vaccin dans les plus brefs délais.
Nous ne relâcherons pas nos efforts en vue de renforcer la collaboration, la coopération et la mise en commun des informations qui sont déjà une réalité sans précédent dans le monde entier.
Nous sommes convaincus que ces efforts contribueront à parer aux carences et aux doubles emplois et nous œuvrerons avec opiniâtreté à la mise à disposition rapide d’un ou de plusieurs vaccins efficaces et sans danger pour tous.
Signataires (en anglais)
Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, USA
Mohamad Assoum, Mercy Global Health
Luigi Aurisicchio, on behalf of Takis Biotech, Italy
Dan Barouch, Center for Virology and Vaccine Research, USA
Trevor Brasel, The University of Texas Medical Branch (UTMB), USA
Jennifer L Bath, ImmunoPrecise Antibodies, Canada
Sina Bavari, Edge BioInnovation Consulting and Management, USA
Maria Elena Bottazzi, Baylor College of Medicine, Houston, USA
Gerhard Beck, Austrian Medicines and Medical Devices, Austria
Tom Brady, Flow Pharma Inc, USA
Kate Broderick, Inovio, USA
Will Brown, Altimmune Inc, USA
Scot Bryson, Orbital Farm, Canada
Ricardo Carrión, Texas Biomedical Research Institute, USA
Miles Carroll, Public Health England, UK
Keith Chappell, University of Queensland, Australia
Daniel S. Chertow, National Institutes of Health, U.S. Department of Health and Human Services, USA
Sandra Cordo, Universidad de Buenos Aires, Argentina
Wian de Jongh, on behalf of the Prevent n-CoV consortium (AdaptVac, ExpreS2ion, Copenhagen University Leiden University Medical Centre, Wageningen University and Tubingen University)
Natalie Dean, University of Florida, USA
Rafael Delgado, Hospital Universitario 12 de Octubre, Spain
Dimiter Dimitrov
David A. Dodd, GeoVax, Inc., USA
Paul Duprex, Center for Vaccine Research, University of Pittsburgh, USA
Luis Enjuanes; Centro Nacional Biotecnología, Spain
Jeremy Farrar, Josie Golding, Charlie Weller, on behalf of Wellcome Trust, UK
Mark Feinberg, Swati Gupta and Ripley Ballou, on behalf of IAVI, USA
Antonella Folgori, on behalf of ReiThera, Italy
Thomas Friedrich, University of Wisconsin, School of Veterinary Medicine, USA
Simon Funnel, Public Health England, UK
Luc Gagnon, Nexelis, Canada
Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, USA
Vipin Garg, Altimmune Inc., USA
Volker Gerdts, on behalf of VIDO-Intervac, University of Saskatchewan, Canada
Nora Gerhards, Wageningen Bioveterinary Research, The Netherlands
Christiane Gerke,Head of Vaccine Programs/Head of Vaccine Innovation Development,InstitutPasteur,France
Carlo Giaquinto, Department of Women and Child Health, University of Padova, Italy
Prakash Ghimire, Tribhuvan University, Nepal
Nikolaj Gilbert, Program for Appropriate Technology in Health (PATH), USA
Sarah Gilbert, University of Oxford, UK
Marion F. Gruber, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Farshad Guirakhoo, GeoVax Inc, USA
Bart L Haagmans, Erasmus Medical Center, The Netherlands
M. Elizabeth Halloran, Center for Inference and Dynamics of Infectious Diseases, Fred Hutchinson Cancer Research Center, and University of Washington, USA
Scott Harris, Altimmune Inc, USA
Hideki Hasegawa, National Institute of Infectious Diseases, Japan
Richard Hatchett, on behalf of the Coalition for Epidemic Preparedness Innovations (CEPI), Norway
James Hayward, Applied DNA Sciences, USA
Sheri Ann Hild
Peter Hotez, Baylor College of Medicine, USA
Youngmee Jee, Seoul National University, College of Medicine, Republic of Korea
Charu Kaushic, Institute of Infection and Immunity, Canadian Institutes of Health Research (CHIR), Government of Canada
Alyson A. Kelvin, Dalhousie University, Canada
Larry D. Kerr, Office of Global Affairs, U.S. Department of Health and Human Services, USA
Bernard Kerscher, PEI, Germany
Jae-Ouk Kim, International Vaccine Institute, Republic of Korea
Seungtaek Kim, Institut Pasteur Korea, Republic of Korea
Jason Kindrachuk, University of Manitoba, Canada
Otfried Kistner, Senior Consultant and Independent Vaccine Expert, Austria
Gary Kobinger, Université Laval, Canada
Marion Koopmans, Viroscience Department, Erasmus Medical Centre, The Netherlands
Philip R. Krause, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Greg Kulnis, Nexelis, Canada
Paul Henri Lambert, Centre of Vaccinology, University of Geneva, Switzerland
Nathalie Landry, Medicago Inc., Canada
Roger Le Grand, Inserm-CEA-Université Paris Saclay, France
Robin Levis, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Mark G Lewis, Bioqual Inc, USA
Joshua Liang, Clover Biopharmaceuticals, China
Jinzhong Lin, on behalf of Fudan University, China
Ira Longini, University of Florida, USA
Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa
Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA
Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research
Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA
Federico Martinón-Torres, Hospital Clínico Universitario de Santiago de Compostela, Spain
Sebastian Maurer-Stroh, on behalf of the GISAID Initiative
John W. Mellors, University of Pittsburgh School of Medicine, USA
Ali Mirazimi, Department of Laboratory medicin, Karolinska institutet, Sweden
Kayvon Modjarrad, Walter Reed Army Institute of Research, USA
Stefan O. Mueller, CureVac, Germany
Vincent J. Munster, National Institutes of Health, U.S. Department of Health and Human Services, USA
Cesar Muñoz-Fontela, Bernhard-Nocht-Institute for Tropical Medicine, Germany
Aysegul Nalca, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), USA
José Manuel Ochoa, Altimmune Inc., USA
Dave O'Connor, University of Wisconsin-Madison, USA
Lidia Oostvogels, CureVac, Germany
Nisreen M. A. Okba, Erasmus Medical Center, The Netherlands
L. Jean Patterson, National Institutes of Health, U.S. Department of Health and Human Services, USA
Joe Payne, on behalf of Arcturus Therapeutics
Jonathan Pearce, UK Research and Innovation (UKRI) and the Medical Research Council (MRC), UK
Stanley Perlman, University of Iowa, USA
Margaret Louise Pitt, WRAIR/ U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
Anuradha Poonepalli, Health Products Regulation Group, Health Sciences Authority, Singapore
Dieter Pullirsch, Austrian Medicines and Medical Devices Agency, Austria
Damian Purcell, Doherty Institute, Australia
Chuan Qin, Institute of Laboratory Animal Sciences (ILAS), CAMS & PUMC, China
Angela Rasmussen, Columbia University Mailman School of Public Health, USA
Scott Roberts, Altimmune Inc., USA
Estefania Rodriguez, Bernhard Nocht Institute for Tropical Medicine, Germany
Ted M Ross, Center for Vaccines and Immunology, University of Georgia, USA
Chad J Roy, Tulane National Primate Research Center and Tulane School of Medicine, USA
Reid Rubsamen, Flow Pharma Inc, USA
Anna Laura Salvati, Italy
Andrew Satz, EVQLV Inc, USA
Hanneke Schuitemaker and Johan Van Hoof, Janssen Pharmaceuticals Companies of Johnson
Robert Shattock, Imperial College, UK
John Shriver, Sanofi, USA
Gale Smith, Novavax Inc. USA
Peter Smith, London School of Hygiene and Tropical Medicine, UK
Isabel Sola, Centro Nacional Biotecnología, Spain
James Southern, Adviser to South African Health Products Regulatory Authority
Jonathan M Spergel, Children’s Hospital of Philadelphia, University of Pennsylvania, USA
Sybil Tasker, Codagenix Inc, USA
Chien-Te Kent Tseng, University of Texas Medical Branch, Galveston, Texas, USA
Jean Marie Vianney Habarugira, on behalf of the European & Developing Countries Clinical Trials Partnership (EDCTP)
Veronika von Messling, on behalf of German Federal Ministry of Education and Research, Germany
Tony T. Wang, Food and Drug Administration, U.S. Department of Health and Human Services, USA
Jeffrey Wolf, Heat Biologics Inc, USA
Ningshao Xia, Xiamen University of China, China
Yingjie Xu, on behalf of Shanghai Jiaotong University, China
Paul R Young, University of Queensland, Australia
Hang Yu, on behalf of Shanghai RNACure, China
Xuefeng Yu, CanSino Biologics, China
Tal Zaks, on behalf of Moderna, USA
Peter Daszak, President, EcoHealth Alliance, New York, USA
U.S. Department of Health and Human Services, USA, Centers for Disease Control and Prevention
U.S. Department of Health and Human Services, USA, Assistant Secretary for Preparedness and Response/Biodefense Advanced Research and Development Authority
Source : who.int
Pour plus d'informations
Aucun commentaire:
Enregistrer un commentaire